Qilian International Holding Group (QLI) Stock Price, News & Analysis

Company Overview

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Key Stats

• Today's Range: $5.41 to $5.41
• 50-Day Range: $3.97 to $6.49
• 52-Week Range: $1.78 to $6.69
• Volume: 300 shs
• Average Volume: 25,095 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

QLI Stock Analysis - Frequently Asked Questions

When did Qilian International Holding Group's stock split?

Qilian International Holding Group shares reverse split before market open on Friday, June 21st 2024. The 1-5 reverse split was announced on Friday, June 21st 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

When did Qilian International Holding Group IPO?

Qilian International Holding Group (QLI) raised $30 million in an initial public offering (IPO) on Tuesday, January 12th 2021. The company issued 5,000,000 shares at $5.00-$7.00 per share. Univest Securities served as the underwriter for the IPO and Loop Capital Markets was co-manager.

What other stocks do shareholders of Qilian International Holding Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Qilian International Holding Group investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), CrowdStrike (CRWD) and Jabil (JBL).

Company Calendar

• Today: 5/14/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:QLI
• CIK: 1779578
• Web: www.qlsyy.net
• Phone: 86-028-6477-5180
• Fax: N/A
• Employees: 280
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $46.47 million
• Price / Sales: N/A
• Cash Flow: $0.32 per share
• Price / Cash Flow: 16.80
• Book Value: $7.69 per share
• Price / Book: 0.70

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 1.39